StockNews.com assumed coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX – Free Report) in a report released on Wednesday morning. The firm issued a hold rating on the medical research company’s stock.
Accelerate Diagnostics Stock Performance
Shares of NASDAQ:AXDX opened at $1.52 on Wednesday. The company has a market cap of $35.99 million, a P/E ratio of -0.37 and a beta of 0.62. Accelerate Diagnostics has a one year low of $0.73 and a one year high of $7.00. The business’s 50-day simple moving average is $1.49 and its 200 day simple moving average is $1.20.
Accelerate Diagnostics (NASDAQ:AXDX – Get Free Report) last announced its earnings results on Thursday, August 8th. The medical research company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.05. The company had revenue of $2.99 million for the quarter, compared to analysts’ expectations of $3.00 million. Analysts predict that Accelerate Diagnostics will post -2.14 earnings per share for the current year.
Institutional Investors Weigh In On Accelerate Diagnostics
About Accelerate Diagnostics
Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.
Read More
- Five stocks we like better than Accelerate Diagnostics
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Powering Your Portfolio: The Utility Sector’s Electrifying Surge
- What is a buyback in stocks? A comprehensive guide for investors
- Adobe Stock Builds Long-Term Value: Consider Buying on the Dip
- 3 Small Caps With Big Return Potential
- Albemarle Jumps as Lithium Stock Buying Frenzy Takes Off
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.